Peptide Inhibitors Against Dengue Virus Infection

Panya, Aussara; Bangphoomi, Kunan; Choowongkomon, Kiattawee; Yenchitsomanus, Pa‐thai

doi:10.1111/cbdd.12309

Cited by 42 publications

(30 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our research group previously reported on peptide inhibitors that bind to the E protein of DENV2. The small peptides EF and MLH40 that we studied and reported could bind to the E protein of DENV2 in the initial step, and this was supported by time‐of‐addition assay. Consistent with our previous small peptide EF and MLH40 findings, pretreatment of DENV2 with the novel peptides in this study caused dramatic reduction in DENV2 infection.…”

Section: Discussionsupporting

confidence: 52%

See 1 more Smart Citation

Novel bioactive peptides demonstrating anti‐dengue virus activity isolated from the Asian medicinal plant Acacia Catechu

et al. 2018

Self Cite

View full text Add to dashboard Cite

The therapeutic activities of food-derived bioactive proteins and peptides are attracting increased attention within the research community. Medicinal plants used in traditional medicines are an excellent source of bioactive proteins and peptides, especially those traditionally prepared by water extraction for use as tea or food supplement. In this study, novel bioactive peptides were isolated from enzymatic digests of 33 Thai medicinal plants. The inhibitory activity of each against dengue virus (DENV) infection was investigated. Of 33 plants, peptides from Acacia catechu extract demonstrated the most pronounced anti-DENV activity. Half maximal inhibitory concentration of 0.18 μg/ml effectively inhibited DENV foci formation. Treatment with 1.25 μg/ml crude peptide extract could reduce virus production less than 100-fold with no observable cell toxicity. Peptide sequences were determined by high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry. Two bioactive peptides isolated from Acacia catechu inhibited DENV foci formation >90% at the concentration of 50 μM; therefore, they are recommended for further investigation as antiviral peptides against DENV infection.

show abstract

Section: Discussionsupporting

confidence: 52%

“…Our research group is committed to the continued search for anti‐DENV agents . We recently reported on our in silico investigation of anti‐DENV peptides . In this in vitro study, we set forth to identify bioactive peptides with anti‐DENV activity in Thai medicinal plants.…”

Section: Introductionmentioning

confidence: 99%

Novel bioactive peptides demonstrating anti‐dengue virus activity isolated from the Asian medicinal plant Acacia Catechu

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Blockade of virus uncoating [135] E hydrophobic pocket target peptides Unknown [136] E hydrophobic pocket target small molecules Unknown [137,138] Zosteric acid derivatives Unknown [139] CBA: Carbohydrate-binding agent; E: Viral glycoprotein; GNA: Galanthus nivalis agglutinin; HHA: Hippeastrum hybrid agglutinin; mAb: Monoclonal antibody; UDA: Urtica dioica agglutinin.…”

Section: Carrageenans Inhibition Of Virus Adsorption and Penetrationmentioning

confidence: 99%

“…Antiviral activity against DENV of other peptides [136] and small molecules [137,138] targeting the hydrophobic pocket of E protein has been reported and it was demonstrated that one of these small inhibitors arrests viral particles within endocytic vesicles [138]. Future studies are needed to unravel the mode of action of this new set of antiviral molecules.…”

Section: • • Other Entry Inhibitorsmentioning

confidence: 99%

Dengue Virus Entry and Trafficking: Perspectives as Antiviral Target for Prevention and Therapy

2015

View full text Add to dashboard Cite

Dengue virus (DENV) is the etiological agent of the most important human viral infection transmitted by mosquitoes in the world. In spite of the serious health threat that dengue represents, at present there are no vaccine or antiviral agents available and treatment of patients consists of supportive therapy. This review will focus on the process of DENV entry into the host cell as a potential target for antiviral therapy. The recent advances in the knowledge of viral and cellular molecules and mechanisms involved in binding, internalization and trafficking of DENV into the host cell until virion uncoating are discussed, together with an overview of the strategies and compounds evaluated for development of antiviral agents targeted to DENV entry. KeywordsDengue is currently the most widespread arbovirosis in the world, with a particularly high prevalence in diverse tropical and subtropical regions of America and Asia [1]. The WHO estimates an occurrence of 50-100 million annual infections, but more recent modelling evaluations increased the number of new possible infections to 390 million per year [2]. There are four serotypes of dengue viruses (DENV), designated DENV-1 to DENV-4, that cocirculate and are transmitted to humans by the bites of the mosquitoes Aedes aegypti and Aedes albopictus. Precisely, the failure in the programs for control of the mosquito vector is one of the reasons for the explosive re-emergence and global spread of dengue in the last few decades in >100 countries, resulting in a serious public health challenge.All serotypes can produce either an inapparent infection or a wide spectrum of clinical outcomes ranging from a mild febrile illness known as dengue fever (DF) to the more severe and life-threatening forms of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [3]. The initial infection with one DENV serotype leads to lifelong protection against homologous reinfection, but only brief and partial protection against infection with other serotypes. In fact, the secondary infection with a heterologous serotype is considered a risk factor for developing DHF and DSS. These severe clinical manifestations have been associated to the phenomenon known as antibody-dependent enhancement (ADE) [3]. In this process, the antibodies elicited by the primary infection bind to the heterotypic virus without neutralization of viral infectivity, and these immune complexes are opsonized into Fc-receptor positive cells leading to an increase in DENV replication and pathogenesis [4,5].DENV is a member of the genus Flavivirus in the family Flaviviridae. The virion is a small spherical particle, 40-50 nm in diameter, containing a single-stranded positive sense RNA included in an inner nucleocapsid and surrounded by a lipid envelope. The virus genome codes for a single polyprotein that is cleaved into three structural proteins (the capsid protein C,

show abstract

“…; Panya et al . ) and self‐inhibitory peptides that were designed from the DENV E protein (Schmidt et al . ,b; Lok et al .…”

Section: Discussionmentioning

confidence: 99%

Anti-dengue virus serotype 2 activity and mode of action of a novel peptide

et al. 2015

View full text Add to dashboard Cite

show abstract

Peptide Inhibitors Against Dengue Virus Infection

Cited by 42 publications

References 39 publications

Novel bioactive peptides demonstrating anti‐dengue virus activity isolated from the Asian medicinal plant Acacia Catechu

Novel bioactive peptides demonstrating anti‐dengue virus activity isolated from the Asian medicinal plant Acacia Catechu

Dengue Virus Entry and Trafficking: Perspectives as Antiviral Target for Prevention and Therapy

Anti-dengue virus serotype 2 activity and mode of action of a novel peptide

Contact Info

Product

Resources

About